A Look At GeneDx Holdings (WGS) Valuation After Breakthrough Device Win And Upgraded 2026 Outlook

Simply Wall St.03-03

GeneDx Holdings (WGS) has just put fresh numbers on the table, reporting its full year 2025 results along with reaffirmed 2026 revenue guidance and an FDA Breakthrough Device designation for its key ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616350258?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","is_english":true,"pubTime":"2026-03-03 01:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616350258","market":"sg","top_or_hot":-1,"title":"A Look At GeneDx Holdings (WGS) Valuation After Breakthrough Device Win And Upgraded 2026 Outlook","media":"Simply Wall St.","content":"<div>\n<p>GeneDx Holdings (WGS) has just put fresh numbers on the table, reporting its full year 2025 results along with reaffirmed 2026 revenue guidance and an FDA Breakthrough Device designation for its key ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/a-look-at-genedx-holdings-wgs-valuation-after-breakthrough-d\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At GeneDx Holdings (WGS) Valuation After Breakthrough Device Win And Upgraded 2026 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At GeneDx Holdings (WGS) Valuation After Breakthrough Device Win And Upgraded 2026 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-03 01:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/a-look-at-genedx-holdings-wgs-valuation-after-breakthrough-d><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GeneDx Holdings (WGS) has just put fresh numbers on the table, reporting its full year 2025 results along with reaffirmed 2026 revenue guidance and an FDA Breakthrough Device designation for its key ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/a-look-at-genedx-holdings-wgs-valuation-after-breakthrough-d\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WGS","symbol_name":"GeneDx Holdings","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/a-look-at-genedx-holdings-wgs-valuation-after-breakthrough-d","article_id":"2616350258","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/a-look-at-genedx-holdings-wgs-valuation-after-breakthrough-d","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616350258","pubTimestamp":1772472343,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"GeneDx Holdings (WGS) has just put fresh numbers on the table, reporting its full year 2025 results along with reaffirmed 2026 revenue guidance and an FDA Breakthrough Device designation for its key genomic tests.\nSee our latest analysis for GeneDx Holdings.\nDespite strong 2025 results, reaffirmed 2026 revenue guidance and the FDA Breakthrough Device designation, GeneDx’s recent share price momentum has been weak, with a 30 day share price return of 17.19% and a 90 day share price return of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"WGS":"GeneDx Holdings"},"translate_title":"突破性设备获胜后GeneDx Holdings(WGS)估值并升级2026年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGS":1.5},"content_text":"GeneDx Holdings (WGS) has just put fresh numbers on the table, reporting its full year 2025 results along with reaffirmed 2026 revenue guidance and an FDA Breakthrough Device designation for its key genomic tests. See our latest analysis for GeneDx Holdings. Despite strong 2025 results, reaffirmed 2026 revenue guidance and the FDA Breakthrough Device designation, GeneDx’s recent share price momentum has been weak, with a 30 day share price return of 17.19% and a 90 day share price return of 50.37%. Over a longer horizon, the 1 year total shareholder return of 15.52% contrasts with a very large 3 year total shareholder return, although the 5 year total shareholder return of 84.01% shows longer term investors have still seen value erosion. If you are watching how genomics and AI are reshaping healthcare, it could be a good moment to scan 28 healthcare AI stocks for other potential opportunities in this space. With the share price down sharply over the past quarter, yet supported by strong revenue growth, improving losses and an FDA Breakthrough Device win, you have to ask: is GeneDx quietly undervalued, or is the market already pricing in future gains? AdvertisementMost Popular Narrative: 53.1% Undervalued GeneDx Holdings’ most followed valuation story pegs fair value at $170.0 per share, more than double the last close of $79.71, setting up a clear valuation gap for investors to interrogate.  Rapid expansion into new and underpenetrated markets, including general pediatrics (driven by American Academy of Pediatrics guidelines), NICU, and additional pediatric specialties, positions GeneDx for substantial future volume and revenue growth as adoption of genomics as a frontline diagnostic tool accelerates. Scaling proprietary AI-powered genomic interpretation platforms and integrating newly acquired Fabric Genomics technology enhances efficiency and accuracy, which should both lower per-sample costs and support margin expansion as the business grows.  Read the complete narrative. Want to see what sits behind that growth story and margin ambition? The narrative leans on compound revenue expansion, rising profitability and a future earnings multiple that assumes meaningful execution. Curious how those moving parts add up to $170.0 a share? Result: Fair Value of $170.0 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you still have to weigh the risk that payer pushback or slower prenatal adoption leaves revenue, margins, and that 88.18x future P/E assumption looking too optimistic. Find out about the key risks to this GeneDx Holdings narrative. Another Angle: Market Pricing Versus Ratios So far the story points to GeneDx looking inexpensive relative to a $170.0 fair value. However, its P/S ratio of 5.5x is much higher than the US Healthcare industry at 1.3x, its peers at 1.9x, and even the 4.9x fair ratio. That kind of premium raises the question of whether the discount is as clear cut as it first appears. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:WGS P/S Ratio as at Mar 2026Next Steps If the mixed signals in this story leave you on the fence, it makes sense to move quickly and review the facts yourself, especially the 4 key rewards that are currently in focus. Looking for more investment ideas? If GeneDx is on your radar, do not stop here, the Simply Wall Street Screener can quickly surface other opportunities that fit the kind of portfolio you want to build.  Pinpoint potential mispricings by scanning 49 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their underlying business strength. Strengthen the foundation of your holdings by checking solid balance sheet and fundamentals stocks screener (41 results) focused on companies with cleaner debt profiles and sturdier financial positions. Spot future market leaders early by reviewing our screener containing 24 high quality undiscovered gems before they land on everyone else’s watchlist.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616350258","isCrawlerRequest":true}